Bone health management in prostate cancer patients receiving androgen deprivation therapy.

نویسندگان

  • Vishnuprabha Dhanapal
  • David J Reeves
چکیده

PURPOSE Patients receiving androgen deprivation therapy undergo a rapid decline in bone mineral density during the first 6 to 12 months of initiating therapy. The World Health Organization has developed and implemented the Fracture Risk Assessment Tool (FRAX) to predict the ten year risk of a major fracture & hip fracture. Additionally, the National Comprehensive Cancer Network and the National Osteoporosis Foundation have developed osteoporosis guidelines. This study aims to characterize the fracture risk (based on the FRAX tool) and the current management of bone health based on national guidelines compliance. METHODS A retrospective chart review of patients receiving a LHRH agonist at our institution was conducted. Data collection commenced upon Institutional Review Board approval and included demographics, past medical history, medication regimen, history of androgen deprivation therapy, bone health and its management. The ten year fracture risk calculated with the collected information using the FRAX tool. RESULTS A total of 174 subjects included with a mean age of 65.5 years, 71.8% had stage II prostate cancer, 97.7% received the LHRH agonist leuprolide for a mean of 13.8 ± 18.1 months. In addition to ADT, 57% of patients had ≥ 2 risk factors for developing osteoporosis. The risk of sustaining a major fracture increased from 4% to 5.6% after the initiation of ADT (P = <0.001). The risk for sustaining a hip fracture rose from 1.3% to 2.2% (P = <0.001). National guideline compliance was found to be 9%, 5% and 3% respectively for obtaining Dual Energy X-ray Absorptiometry (DEXA) scans, calcium supplementation, and vitamin D supplementation. CONCLUSION In addition to predisposing risk factors for osteoporosis, ADT significantly increases the fracture risk in the prostate cancer population. There is room for improvement in the management of bone health as some intervention could have been made in over 90% of patients evaluated.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options.

Osteoporosis and bone fractures are frequently overlooked complications of androgen deprivation therapy in men with nonmetastatic prostate cancer. All such patients should have their bone mineral density (BMD) monitored and be offered preventive measures, such as calcium and vitamin D supplementation; patients with low BMD should be offered treatment. Several agents, including bisphosphonates, ...

متن کامل

Influence of insolation on osteoporosis progression in androgen deprived nonmetastatic prostate cancer patients.

Prostate cancer is a major public health problem in all the developed countries. Increasing numbers of men with nonmetastatic prostate cancer are receiving long-term androgen deprivation therapy (ADT). ADT is associated the loss of bone mineral density and a increased risk of bone fractures. The standard recommendations for male bone health include above all optimizing calcium and vitamin D int...

متن کامل

Androgen-deprivation bone loss in patients with prostate cancer.

An increasing number of men with prostate cancer being treated with androgen-deprivation therapy (ADT) are at increased risk for developing osteoporosis. Osteoporosis often is overlooked in men and can have significant adverse economic effects and reduce quality of life, particularly if a fracture occurs. Nurses play a major role in identifying men who are at risk because of lifestyle factors a...

متن کامل

The incidence of skeletal complications experienced by patients with metastatic prostate cancer is illustrated by the placebo group of a recent study of zoledronic acid in men with hormone-refractory prostate cancer

1522. 27.Saad F, Gleason D, Murray R, et al.,“Long-term reduction of bone pain with zoledronic acid in patients with advanced prostate cancer metastatic to bone”, [poster], Poster presented at:American Urological Association Annual Meeting;April 26 May 1, 2003; Chicago, Illinois,Abstract 1473. 28.Major P P, Cook R J, Chen B-L and Zheng M,“Zoledronic acid reduces the need for radiation to bone i...

متن کامل

Utilization of bone densitometry for prediction and administration of bisphosphonates to prevent osteoporosis in patients with prostate cancer without bone metastases receiving antiandrogen therapy

BACKGROUND Prostate cancer subjects with prostate-specific antigen (PSA) relapse who are treated with androgen deprivation therapy (ADT) are recommended to have baseline and serial bone densitometry and receive bisphosphonates. The purpose of this community population study was to assess the utilization of bone densitometry and bisphosphonate therapy in men receiving ADT for non-metastatic pros...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

دوره 18 1  شماره 

صفحات  -

تاریخ انتشار 2012